Food and Drug Administration (FDA)
Nurixâs B-cell cancer drug on partial hold by FDA over manufacturing issues
Anika Sharma
Nurix Therapeutics has temporarily halted a phase 1 trial for its B-cell malignancy drug, NX-2127, as it undertakes a manufacturing ...
Aldeyra faces FDA rejection risk for dry eye drug due to review issues
Anika Sharma
Aldeyra Therapeutics confronts a daunting situation as regulatory concerns cast doubt on the future of its dry eye disease medication, ...
